Currently, indicators such as Expression of PD-L1 protein (1–3), tumor mutation burden (TMB) (4) and microsatellite instability (MSI) (5) play a role in predicting the efficacy of immunotherapy. The gene discussed is CD274; the disease is neoplasm.